Refractory Hypercholesterolemia in Heterozygous Familial Hypercholesterolemia Treated with Evinacumab

We present a patient with HeFH genotype that did not adequately respond to the combination of these therapies, much like a homozygous FH patient. She required addition of evinucamab, a monoclonal antibody to ANGPTL3 approved for HoFH, to bring her LDL and total cholesterol to target.

Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Tiffany Haynes, Laura Grace Kukuc, Robert Fishberg Tags: Genetic Disorders Source Type: research